Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Dedusting equipment and techniques address problems associated with tablet manufacturing dust accumulation.

Addressing Dust Accumulation in Tablet Manufacturing

Asking the right questions is crucial to establishing a biopharmaceutical facility design.

Designing a Biomanufacturing Facility Incorporating Single-Use Technologies

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

The pharma company revealed in a fourth quarter call that it will improve its cell-culture capabilities by focusing on the use of naïve, highly proliferative cells to manufacture its CAR-T drug candidate.

Kite Pharma Stresses Importance of Cell-Culturing Techniques

The author lists five key areas to consider when selecting a CDMO to develop highly potent formulations.

Outsourcing Formulation Development for High-Potency Compounds

Matt Bundenthal is direct sales and communications manager at Fette Compacting America, www.fetteamerica.com .

Tablet presses require regular inspection and maintenance to prevent premature wear and tableting problems.

Best Practice: Preventive Maintenance Keeps Tablet Presses Running Smoothly

Richard Denk is Head Sales Containment at SKAN AG, www.skan.ch, Richard.Denk@skan.ch.

Manufacturing of antibody drug conjugates requires high-containment solutions, such as high-performance aseptic isolators.

Best Practices for Handling Antibody Drug Conjugates

The course, intended for healthcare professionals, provides an overview of biosimilar products and FDA’s biosimilar product development programs.

FDA Releases Online Course on Biosimilars

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Vaccine R&D has grown exponentially in recent years, spurred by ethical and medical needs to combat lethal infectious outbreaks and increased funding from public and private agencies and organizations.

Vaccines Prove Effective and Cost-Effective

There are no clinically meaningful differences between Celltrion’s CT-P13 and Remicade, according to an FDA briefing released ahead of the formal panel meeting.

Celltrion’s Biosimilar to Remicade Likely to be Approved for All Indications

Although switching has occurred in European markets for some biosimilars, most biosimilar manufacturers will focus on securing new users, according to Merck.